708 related articles for article (PubMed ID: 28536008)
1. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
2. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Ma C; Huang T; Ding YC; Yu W; Wang Q; Meng B; Luo SX
Int J Clin Exp Pathol; 2015; 8(6):6533-9. PubMed ID: 26261532
[TBL] [Abstract][Full Text] [Related]
4. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
5. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
6. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
Mittal A; Chitkara D; Behrman SW; Mahato RI
Biomaterials; 2014 Aug; 35(25):7077-87. PubMed ID: 24836307
[TBL] [Abstract][Full Text] [Related]
8. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Tu MJ; Ho PY; Zhang QY; Jian C; Qiu JX; Kim EJ; Bold RJ; Gonzalez FJ; Bi H; Yu AM
Cancer Lett; 2019 Feb; 442():82-90. PubMed ID: 30389433
[TBL] [Abstract][Full Text] [Related]
9. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
[TBL] [Abstract][Full Text] [Related]
11. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W
Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
[TBL] [Abstract][Full Text] [Related]
15. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
16. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.
Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI
Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326
[TBL] [Abstract][Full Text] [Related]
17. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
18. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
19. miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells.
Liang C; Wang Z; Li YY; Yu BH; Zhang F; Li HY
Tumour Biol; 2015 Dec; 36(12):9395-403. PubMed ID: 26113407
[TBL] [Abstract][Full Text] [Related]
20. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
